Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2013 Nov 1;3(11):885-93.
doi: 10.7150/thno.5513.

Bringing New PET drugs to clinical practice - a regulatory perspective

Joseph C Hung  1
Affiliations
Review

Bringing New PET drugs to clinical practice - a regulatory perspective

Joseph C Hung. Theranostics. .

Abstract

The regulatory framework for radioactive drugs, in particular those used in positron emission tomography (PET) scans, has been gradually established since the release of the Food and Drug Administration Modernization Act in 1997. Various guidances specially tailored to accommodate special properties of PET drugs have been issued by the Food and Drug Administration (FDA) in order to ensure this valuable technology (i.e., PET molecular imaging) will continue to be available to patients and yet the safety and efficacy of PET drugs are well regulated so that public health will be protected. This article presents several key elements of this regulatory framework for PET drugs. New regulatory avenues proposed by the FDA to facilitate the research and development process to bring more new PET drugs to clinical practice, as well as to foster the opportunity of using "orphan" PET drugs in clinical practice are also discussed in this paper.

Keywords: FDA; IND; NDA; PET drugs; RDRC; expanded access IND.; exploratory IND; regulations.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interests: The author has declared that no conflict of interest exists.

References

    1. US FDA: Silver Spring, MD. Rieves RD. 2012 FDA update. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/Manufactur....
    1. Medical Imaging Drugs Advisory Committee Roster. Silver Spring, MD: FDA; http://www.fda.gov/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/M....
    1. Nunn AD. The cost of developing imaging agents for routine clinical use. Invest Radiol. 2006;41:206–212. - PubMed
    1. Hoffman JM, Gambhir SS, Kelloff GJ. Regulatory and reimbursement challenges for molecular imaging. Radiology. 2007;245:645–660. - PubMed
    1. Agdeppa ED, Spilker ME. A review of imaging agent development. The AAPS Journal. 2009;11:286–299. - PMC - PubMed

MeSH terms

LinkOut - more resources